$IOR
INCOME OPPORTUNITY REALTY INVESTORS INC /TX/

2024 Q3 Form 10-Q Financial Statement

#000199937124009758 Filed on August 08, 2024

View on sec.gov

Income Statement

Concept 2024 Q3 2024 Q2
Revenue
YoY Change
Cost Of Revenue
YoY Change
Gross Profit
YoY Change
Gross Profit Margin
Selling, General & Admin $97.00K $114.0K
YoY Change -77.95% -75.0%
% of Gross Profit
Research & Development
YoY Change
% of Gross Profit
Depreciation & Amortization
YoY Change
% of Gross Profit
Operating Expenses $97.00K $114.0K
YoY Change -77.95% -75.0%
Operating Profit -$97.00K -$114.0K
YoY Change -77.8% -75.0%
Interest Expense $1.614M $1.585M
YoY Change -35.85% -42.94%
% of Operating Profit
Other Income/Expense, Net
YoY Change
Pretax Income $1.517M $1.471M
YoY Change -27.07% -36.65%
Income Tax $319.0K $309.0K
% Of Pretax Income 21.03% 21.01%
Net Earnings $1.198M $1.162M
YoY Change -27.08% -36.64%
Net Earnings / Revenue
Basic Earnings Per Share $0.29 $0.28
Diluted Earnings Per Share $0.29 $0.28
COMMON SHARES
Basic Shares Outstanding 4.066M shares 4.078M shares
Diluted Shares Outstanding 4.070M shares 4.107M shares

Balance Sheet

Concept 2024 Q3 2024 Q2
SHORT-TERM ASSETS
Cash & Short-Term Investments $14.00K $16.00K
YoY Change 700.0%
Cash & Equivalents $14.00K $16.00K
Short-Term Investments
Other Short-Term Assets
YoY Change
Inventory
Prepaid Expenses
Receivables $109.5M $108.3M
Other Receivables $109.5M $108.3M
Total Short-Term Assets $109.7M $108.7M
YoY Change 4.11% 4.78%
LONG-TERM ASSETS
Property, Plant & Equipment
YoY Change
Goodwill
YoY Change
Intangibles
YoY Change
Long-Term Investments
YoY Change
Other Assets
YoY Change
Total Long-Term Assets $11.15M $11.17M
YoY Change -0.24% 0.0%
TOTAL ASSETS
Total Short-Term Assets $109.7M $108.7M
Total Long-Term Assets $11.15M $11.17M
Total Assets $120.8M $119.8M
YoY Change 3.69% 4.32%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable $3.000K $0.00
YoY Change 200.0% -100.0%
Accrued Expenses
YoY Change
Deferred Revenue
YoY Change
Short-Term Debt $0.00 $0.00
YoY Change
Long-Term Debt Due
YoY Change
Total Short-Term Liabilities $3.000K
YoY Change
LONG-TERM LIABILITIES
Long-Term Debt $0.00 $0.00
YoY Change
Other Long-Term Liabilities
YoY Change
Total Long-Term Liabilities $0.00 $0.00
YoY Change
TOTAL LIABILITIES
Total Short-Term Liabilities $3.000K
Total Long-Term Liabilities $0.00 $0.00
Total Liabilities $3.000K $0.00
YoY Change -100.0%
SHAREHOLDERS EQUITY
Retained Earnings $60.57M $59.37M
YoY Change 11.02% 12.2%
Common Stock $62.00M $62.00M
YoY Change 0.0% 0.0%
Preferred Stock
YoY Change
Treasury Stock (at cost) $1.749M $1.534M
YoY Change 4384.62% 3833.33%
Treasury Stock Shares
Shareholders Equity $120.8M $119.8M
YoY Change
Total Liabilities & Shareholders Equity $120.8M $119.8M
YoY Change 3.69% 4.32%

Cashflow Statement

Concept 2024 Q3 2024 Q2
OPERATING ACTIVITIES
Net Income $1.198M $1.162M
YoY Change -27.08% -36.64%
Depreciation, Depletion And Amortization
YoY Change
Cash From Operating Activities $186.0K -$20.00K
YoY Change 1760.0% 400.0%
INVESTING ACTIVITIES
Capital Expenditures
YoY Change
Acquisitions
YoY Change
Other Investing Activities $27.00K
YoY Change
Cash From Investing Activities $27.00K
YoY Change
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities -215.0K 0.000
YoY Change
NET CHANGE
Cash From Operating Activities 186.0K -20.00K
Cash From Investing Activities 27.00K
Cash From Financing Activities -215.0K 0.000
Net Change In Cash -2.000K -20.00K
YoY Change -120.0% 400.0%
FREE CASH FLOW
Cash From Operating Activities $186.0K -$20.00K
Capital Expenditures
Free Cash Flow
YoY Change

Facts In Submission

Frame Concept Type Concept / XBRL Key Value Unit
CY2023Q2 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
4168414 shares
CY2023Q2 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
4168414 shares
us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
4092618 shares
us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
0.57
us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
4092618 shares
us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
4168414 shares
us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
4168414 shares
CY2024Q2 us-gaap Stockholders Equity
StockholdersEquity
119831000 usd
us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
294000 usd
CY2024Q2 us-gaap Revenues
Revenues
usd
CY2023Q2 us-gaap Revenues
Revenues
usd
us-gaap Revenues
Revenues
usd
us-gaap Revenues
Revenues
usd
us-gaap Increase Decrease In Accounts Payable
IncreaseDecreaseInAccountsPayable
usd
us-gaap Payments For Repurchase Of Common Stock
PaymentsForRepurchaseOfCommonStock
usd
us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
usd
CY2024Q2 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.01
CY2023Q4 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.01
CY2024Q2 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
10000000 shares
CY2023Q4 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
10000000 shares
CY2024Q2 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
4173675 shares
CY2023Q4 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
4173675 shares
CY2024Q2 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
4078106 shares
CY2023Q4 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
4110714 shares
CY2024Q2 us-gaap Common Stock Value
CommonStockValue
42000 usd
CY2023Q4 us-gaap Common Stock Value
CommonStockValue
42000 usd
CY2024Q2 us-gaap Treasury Stock Common Shares
TreasuryStockCommonShares
95569 shares
CY2023Q4 us-gaap Treasury Stock Common Shares
TreasuryStockCommonShares
95569 shares
CY2024Q2 us-gaap Treasury Stock Value
TreasuryStockValue
1534000 usd
CY2023Q4 us-gaap Treasury Stock Value
TreasuryStockValue
947000 usd
CY2024Q2 us-gaap Additional Paid In Capital Common Stock
AdditionalPaidInCapitalCommonStock
61955000 usd
CY2023Q4 us-gaap Additional Paid In Capital Common Stock
AdditionalPaidInCapitalCommonStock
61955000 usd
CY2024Q2 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
59368000 usd
CY2023Q4 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
57028000 usd
CY2024Q2 us-gaap Stockholders Equity
StockholdersEquity
119831000 usd
CY2023Q4 us-gaap Stockholders Equity
StockholdersEquity
118078000 usd
CY2024Q2 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
119831000 usd
CY2023Q4 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
118078000 usd
CY2024Q2 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
93000 usd
CY2023Q2 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
76000 usd
us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
159000 usd
CY2024Q2 ior Advisory Fee To Related Party
AdvisoryFeeToRelatedParty
21000 usd
CY2023Q2 ior Advisory Fee To Related Party
AdvisoryFeeToRelatedParty
380000 usd
ior Advisory Fee To Related Party
AdvisoryFeeToRelatedParty
50000 usd
ior Advisory Fee To Related Party
AdvisoryFeeToRelatedParty
699000 usd
CY2024Q2 us-gaap Costs And Expenses
CostsAndExpenses
114000 usd
CY2023Q2 us-gaap Costs And Expenses
CostsAndExpenses
456000 usd
us-gaap Costs And Expenses
CostsAndExpenses
209000 usd
us-gaap Costs And Expenses
CostsAndExpenses
993000 usd
CY2024Q2 us-gaap Operating Income Loss
OperatingIncomeLoss
-114000 usd
CY2023Q2 us-gaap Operating Income Loss
OperatingIncomeLoss
-456000 usd
us-gaap Operating Income Loss
OperatingIncomeLoss
-209000 usd
us-gaap Operating Income Loss
OperatingIncomeLoss
-993000 usd
CY2024Q2 us-gaap Interest Income Expense Nonoperating Net
InterestIncomeExpenseNonoperatingNet
1585000 usd
CY2023Q2 us-gaap Interest Income Expense Nonoperating Net
InterestIncomeExpenseNonoperatingNet
2778000 usd
us-gaap Interest Income Expense Nonoperating Net
InterestIncomeExpenseNonoperatingNet
3171000 usd
us-gaap Interest Income Expense Nonoperating Net
InterestIncomeExpenseNonoperatingNet
4644000 usd
CY2024Q2 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
309000 usd
CY2023Q2 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
488000 usd
us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
622000 usd
us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
767000 usd
CY2024Q2 us-gaap Net Income Loss
NetIncomeLoss
1162000 usd
CY2023Q2 us-gaap Net Income Loss
NetIncomeLoss
1834000 usd
us-gaap Net Income Loss
NetIncomeLoss
2340000 usd
us-gaap Net Income Loss
NetIncomeLoss
2884000 usd
CY2024Q2 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
0.28
CY2024Q2 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
0.28
CY2023Q2 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
0.44
CY2023Q2 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
0.44
us-gaap Earnings Per Share Basic
EarningsPerShareBasic
0.57
us-gaap Earnings Per Share Basic
EarningsPerShareBasic
0.69
us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
0.69
CY2024Q2 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
4107131 shares
CY2024Q2 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
4107131 shares
CY2024Q1 us-gaap Stockholders Equity
StockholdersEquity
118669000 usd
CY2024Q2 us-gaap Net Income Loss
NetIncomeLoss
1162000 usd
CY2024Q2 us-gaap Stockholders Equity
StockholdersEquity
119831000 usd
CY2023Q1 us-gaap Stockholders Equity
StockholdersEquity
113035000 usd
CY2023Q2 us-gaap Net Income Loss
NetIncomeLoss
1834000 usd
CY2023Q2 us-gaap Stockholders Equity
StockholdersEquity
114869000 usd
CY2023Q4 us-gaap Stockholders Equity
StockholdersEquity
118078000 usd
us-gaap Net Income Loss
NetIncomeLoss
2340000 usd
us-gaap Treasury Stock Value Acquired Cost Method
TreasuryStockValueAcquiredCostMethod
587000 usd
CY2022Q4 us-gaap Stockholders Equity
StockholdersEquity
111985000 usd
CY2022Q4 us-gaap Stockholders Equity
StockholdersEquity
111985000 usd
us-gaap Net Income Loss
NetIncomeLoss
2884000 usd
CY2023Q2 us-gaap Stockholders Equity
StockholdersEquity
114869000 usd
CY2023Q2 us-gaap Stockholders Equity
StockholdersEquity
114869000 usd
us-gaap Net Income Loss
NetIncomeLoss
2884000 usd
us-gaap Increase Decrease In Notes Receivable Related Parties
IncreaseDecreaseInNotesReceivableRelatedParties
33000 usd
us-gaap Increase Decrease In Notes Receivable Related Parties
IncreaseDecreaseInNotesReceivableRelatedParties
-11000 usd
us-gaap Increase Decrease In Accounts Receivable Related Parties
IncreaseDecreaseInAccountsReceivableRelatedParties
1775000 usd
us-gaap Increase Decrease In Accounts Receivable Related Parties
IncreaseDecreaseInAccountsReceivableRelatedParties
2896000 usd
us-gaap Increase Decrease In Accounts Payable
IncreaseDecreaseInAccountsPayable
-3000 usd
us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
532000 usd
us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-4000 usd
us-gaap Payments For Repurchase Of Common Stock
PaymentsForRepurchaseOfCommonStock
587000 usd
us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
-587000 usd
us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
-55000 usd
us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
-4000 usd
CY2023Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
71000 usd
CY2022Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
6000 usd
CY2024Q2 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
16000 usd
CY2023Q2 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
2000 usd
CY2024Q2 srt Stock Repurchase Program Number Of Shares Authorized To Be Repurchased
StockRepurchaseProgramNumberOfSharesAuthorizedToBeRepurchased
1650000 shares
us-gaap Treasury Stock Shares Acquired
TreasuryStockSharesAcquired
32608 shares
us-gaap Treasury Stock Value Acquired Cost Method
TreasuryStockValueAcquiredCostMethod
587000 usd
CY2024Q2 us-gaap Stock Repurchase Program Remaining Number Of Shares Authorized To Be Repurchased
StockRepurchaseProgramRemainingNumberOfSharesAuthorizedToBeRepurchased
524931 shares

Files In Submission

Name View Source Status
0001999371-24-009758-index-headers.html Edgar Link pending
0001999371-24-009758-index.html Edgar Link pending
0001999371-24-009758.txt Edgar Link pending
0001999371-24-009758-xbrl.zip Edgar Link pending
ex31-1.htm Edgar Link pending
ex31-2.htm Edgar Link pending
ex32-1.htm Edgar Link pending
Financial_Report.xlsx Edgar Link pending
ior-10q_063024.htm Edgar Link pending
ior-20240630.xsd Edgar Link pending
FilingSummary.xml Edgar Link unprocessable
ior-10q_063024_htm.xml Edgar Link completed
MetaLinks.json Edgar Link pending
R1.htm Edgar Link pending
R10.htm Edgar Link pending
R11.htm Edgar Link pending
R12.htm Edgar Link pending
R13.htm Edgar Link pending
R14.htm Edgar Link pending
R15.htm Edgar Link pending
R16.htm Edgar Link pending
R17.htm Edgar Link pending
R18.htm Edgar Link pending
R19.htm Edgar Link pending
R2.htm Edgar Link pending
R3.htm Edgar Link pending
R4.htm Edgar Link pending
R5.htm Edgar Link pending
R6.htm Edgar Link pending
R7.htm Edgar Link pending
R8.htm Edgar Link pending
R9.htm Edgar Link pending
report.css Edgar Link pending
Show.js Edgar Link pending
ior-20240630_def.xml Edgar Link unprocessable
ior-20240630_lab.xml Edgar Link unprocessable
ior-20240630_pre.xml Edgar Link unprocessable
ior-20240630_cal.xml Edgar Link unprocessable